ATE246676T1 - Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren - Google Patents

Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren

Info

Publication number: ATE246676T1
Authority: AT; Austria
Prior art keywords: carbons; retinoid; receptors; alkyl; selective activity
Prior art date: 1998-10-01

Application number

AT99970084T

Other languages

English (en)

Inventor

Jayasree Vasudevan

Vidyasagar Vuligonda

Richard L Beard

Roshantha A Chandraratna

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-01

Filing date

1999-09-21

Publication date

2003-08-15

1999-09-21 Application filed by Allergan Inc filed Critical Allergan Inc

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE246676T1 publication Critical patent/ATE246676T1/de

Links

230000000694 effects Effects 0.000 title abstract 2
102000034527 Retinoid X Receptors Human genes 0.000 title 1
108010038912 Retinoid X Receptors Proteins 0.000 title 1
150000003530 tetrahydroquinolines Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
SDVVLIIVFBKBMG-ONEGZZNKSA-N (E)-penta-2,4-dienoic acid Chemical group OC(=O)\C=C\C=C SDVVLIIVFBKBMG-ONEGZZNKSA-N 0.000 abstract 1
241001061127 Thione Species 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000004492 retinoid derivatives Chemical class 0.000 abstract 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Obesity (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT99970084T 1998-10-01 1999-09-21 Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren ATE246676T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/164,949 US6048873A (en)	1998-10-01	1998-10-01	Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
PCT/US1999/021857 WO2000020397A1 (en)	1998-10-01	1999-09-21	Tetrahydroquinoline derivatives having selective activity for retinoid x receptors

Publications (1)

Publication Number	Publication Date
ATE246676T1 true ATE246676T1 (de)	2003-08-15

Family

ID=22596785

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99970084T ATE246676T1 (de)	1998-10-01	1999-09-21	Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren
AT03016595T ATE310727T1 (de)	1998-10-01	1999-09-21	Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT03016595T ATE310727T1 (de)	1998-10-01	1999-09-21	Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren

Country Status (10)

Country	Link
US (1)	US6048873A (de)
EP (2)	EP1354878B1 (de)
JP (1)	JP2002526534A (de)
AT (2)	ATE246676T1 (de)
AU (1)	AU763108B2 (de)
CA (1)	CA2346037A1 (de)
DE (2)	DE69928583T2 (de)
DK (1)	DK1117648T3 (de)
ES (1)	ES2201835T3 (de)
WO (1)	WO2000020397A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2335335A (en) *	1998-03-13	1999-09-15	Northern Telecom Ltd	Carrying speech-band signals over power lines
US6291677B1 (en)	2000-08-29	2001-09-18	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en)	2000-08-29	2001-11-06	Allergan Sales, Inc.	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6388105B1 (en) *	2001-09-27	2002-05-14	Allergan Sales, Inc.	Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en)	2002-04-30	2004-04-13	Allergan, Inc.	Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2004032848A2 (en) *	2002-10-04	2004-04-22	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) *	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
US6683092B1 (en)	2003-04-09	2004-01-27	Allergan, Inc.	[3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en)	2003-06-03	2004-05-11	Allergan, Inc.	(1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) *	2003-06-26	2005-08-30	Allergan, Inc.	5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en)	2003-10-29	2005-05-03	Allergan, Inc.	7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
US7476673B2 (en) *	2003-12-30	2009-01-13	Allergan, Inc.	Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2006091674A1 (en) *	2005-02-24	2006-08-31	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
CN101316583A (zh)	2005-09-30	2008-12-03	生命医药公司	用特异性rxr激动剂治疗癌症
EP1937640A2 (de) *	2005-09-30	2008-07-02	Janssen Pharmaceutica N.V.	1,2,3,5-tetrahydrocyclopental[c]chinolin-4-onderivate als rxr-agonisten zur behandlung von dyslipidämie, hypercholesterinämie und diabetes
CN101316827A (zh) *	2005-09-30	2008-12-03	詹森药业有限公司	作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的杂环酰胺衍生物
EP1937641A2 (de) *	2005-09-30	2008-07-02	Janssen Pharmaceutica, N.V.	Dihydro-[1h]-chinolin-2-onderivate als rxr-agonisten zur behandlung von dyslipidämie, hypercholesterinämie und diabetes
US20070185055A1 (en) *	2006-02-06	2007-08-09	Guang Liang Jiang	Method for treating cachexia with retinoid ligands
US20090197878A1 (en) *	2008-02-01	2009-08-06	Wyeth	SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
US10653650B2 (en)	2011-12-13	2020-05-19	Io Therapeutics, Inc.	Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2013090616A1 (en)	2011-12-13	2013-06-20	Io Therapeutics, Inc.	Autoimmune disorder treatment using rxr agonists
RU2720237C2 (ru)	2013-11-18	2020-04-28	Форма Терапеутикс, Инк.	Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh)	2013-11-18	2019-12-31	福马疗法公司	作为bet溴域抑制剂的四氢喹啉组成物
CN116077626A (zh)	2015-10-31	2023-05-09	Io治疗公司	使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
US10835507B2 (en)	2016-03-10	2020-11-17	Io Therapeutics, Inc.	Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
KR102605349B1 (ko)	2016-03-10	2023-11-22	아이오 테라퓨틱스, 인크.	Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
CA3076373A1 (en)	2017-09-20	2019-03-28	Io Therapeutics, Inc.	Treatment of disease with esters of selective rxr agonists
AU2018367653B2 (en) *	2017-11-17	2020-11-12	Io Therapeutics, Inc.	Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
US10966950B2 (en)	2019-06-11	2021-04-06	Io Therapeutics, Inc.	Use of an RXR agonist in treating HER2+ cancers
CA3242047A1 (en)	2021-12-07	2023-06-15	Io Therapeutics, Inc.	Use of an rxr agonist in treating drug resistant her2+ cancers
AU2022408160A1 (en)	2021-12-07	2024-06-06	Board Of Regents, The University Of Texas System	Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264578A (en) *	1987-03-20	1993-11-23	Allergan, Inc.	Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
JP4001618B2 (ja) *	1991-12-18	2007-10-31	ザソールクインスチチュートフォアバイオロジカルスタディズ	レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物
ATE195716T1 (de) *	1992-04-22	2000-09-15	Ligand Pharm Inc	Retinoid-x rezeptor selektive verbindungen
ES2129115T3 (es) *	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5455265A (en) *	1993-02-11	1995-10-03	Allergan, Inc.	Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
PL180048B1 (en) *	1994-08-10	2000-12-29	Fhoffmann La Roche Ag	Ligands of retinic acid x-receptors
JP3826182B2 (ja) *	1994-10-31	2006-09-27	エーザイ・アール・アンド・ディー・マネジメント株式会社	モノ又はポリエンカルボン酸誘導体
US5616712A (en) *	1995-05-16	1997-04-01	Allergan	Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5675033A (en) *	1995-06-06	1997-10-07	Allergan	2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) *	1995-09-01	1998-07-07	Allergan, Inc.	Method of identifying negative hormone and/or antagonist activities
WO1997012853A1 (en) *	1995-10-06	1997-04-10	Ligand Pharmaceuticals Incorporated	Dimer-selective rxr modulators and methods for their use
AU7598596A (en) *	1995-11-01	1997-05-22	Allergan, Inc.	Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5739338A (en) *	1996-11-05	1998-04-14	Allergan	N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

1998
- 1998-10-01 US US09/164,949 patent/US6048873A/en not_active Expired - Fee Related
1999
- 1999-09-21 AT AT99970084T patent/ATE246676T1/de not_active IP Right Cessation
- 1999-09-21 JP JP2000574514A patent/JP2002526534A/ja active Pending
- 1999-09-21 WO PCT/US1999/021857 patent/WO2000020397A1/en not_active Ceased
- 1999-09-21 AT AT03016595T patent/ATE310727T1/de not_active IP Right Cessation
- 1999-09-21 AU AU60547/99A patent/AU763108B2/en not_active Ceased
- 1999-09-21 EP EP03016595A patent/EP1354878B1/de not_active Expired - Lifetime
- 1999-09-21 DE DE69928583T patent/DE69928583T2/de not_active Expired - Fee Related
- 1999-09-21 CA CA002346037A patent/CA2346037A1/en not_active Abandoned
- 1999-09-21 ES ES99970084T patent/ES2201835T3/es not_active Expired - Lifetime
- 1999-09-21 DK DK99970084T patent/DK1117648T3/da active
- 1999-09-21 DE DE69910231T patent/DE69910231T2/de not_active Expired - Fee Related
- 1999-09-21 EP EP99970084A patent/EP1117648B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69928583D1 (de)	2005-12-29
DE69910231D1 (de)	2003-09-11
EP1117648A1 (de)	2001-07-25
EP1354878B1 (de)	2005-11-23
EP1354878A2 (de)	2003-10-22
WO2000020397A1 (en)	2000-04-13
CA2346037A1 (en)	2000-04-13
EP1354878A3 (de)	2003-12-10
DE69928583T2 (de)	2006-08-10
ES2201835T3 (es)	2004-03-16
HK1057213A1 (en)	2004-03-19
EP1117648B1 (de)	2003-08-06
US6048873A (en)	2000-04-11
JP2002526534A (ja)	2002-08-20
DE69910231T2 (de)	2004-06-09
ATE310727T1 (de)	2005-12-15
AU763108B2 (en)	2003-07-10
HK1039121A1 (en)	2002-04-12
DK1117648T3 (da)	2003-11-17
AU6054799A (en)	2000-04-26

Legal Events

Date	Code	Title	Description
2004-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE246676T1 (de)	2003-08-15	Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren
EP1043317A4 (de)	2003-03-05	Pyridazinderivate und dieselben als aktive bestandteile enthaltende medikamente
DE3688374D1 (de)	1993-06-03	Pyrazolsulfonamidderivat, verfahren zu seiner herstellung und dieses enthaltendes herbizid.
FI982436A0 (fi)	1998-11-10	Kondensoituneet heterosykliset yhdisteet
DE69331414D1 (de)	2002-02-07	Depsipeptide, herstellung und anwendung
BR8704582A (pt)	1988-04-26	Processo para preparar derivados de piridinacarboxamida
ATE126219T1 (de)	1995-08-15	Benzimidazolderivate, verfahren zu deren herstellung und anwendung.
NO981269D0 (no)	1998-03-20	Forbindelser som forsterker virkningen av retinoider
KR960703902A (ko)	1996-08-31	피라졸유도체
ATE164582T1 (de)	1998-04-15	1-methylcarbapenemderivate und verfahren zu ihrer herstellung
ATE279411T1 (de)	2004-10-15	Fluorszierende marker
DK0783001T3 (da)	2000-04-10	Androstenoner
ATE73451T1 (de)	1992-03-15	Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen.
ATE73452T1 (de)	1992-03-15	Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen.
TW427979B (en)	2001-04-01	A condensed piperidine compound
KR920004353A (ko)	1992-03-27	4,5,6,7-테트라하이드로-3-아릴-인다졸, 그의 제조방법 및 제초제로의 용도
KR970704715A (ko)	1997-09-06	사카린 유도체(Saccharin Derivatives)
ATE200779T1 (de)	2001-05-15	Triazin-derivate
ATE241594T1 (de)	2003-06-15	N-phenylacetoacetamide und verfahren zu ihrer herstellung
DE69815380D1 (de)	2003-07-10	N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind
EA200500032A1 (ru)	2005-08-25	Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
KR930019598A (ko)	1993-10-18	인단-1,3-디온유도체 및 이들을 유효성분으로 함유한 제초제
KR890002015A (ko)	1989-04-07	2-니트로-5-(치환된 피리딜옥시)벤조히드록 심산 유도체
KR940014390A (ko)	1994-07-18	3'-o-프로파르길-트리플루오로티미딘의 티오에스테르 유도체, 이의 제조방법 및 이를 유효 성분으로 하는 제암제
KR970042528A (ko)	1997-07-24	β-메톡시아크릴레이트기를 함유하는 이소티아졸론 유도체